mediwound
announces
fda
acceptance
biologics
license
application
nexobrid
treatment
severe
thermal
burns
yavne
israel
globe
newswire
mediwound
nasdaq
mdwd
mediwound
biopharmaceutical
company
bringing
innovative
therapies
address
unmet
needs
severe
burn
wound
management
today
announced
food
drug
administration
fda
accepted
review
recently
submitted
biologics
license
application
bla
eschar
removal
debridement
adults
deep
thermal
burns
fda
assigned
prescription
drug
user
fee
act
pdufa
target
date
june
addition
fda
communicated
currently
planning
hold
advisory
committee
meeting
discuss
application
fda
acceptance
nexobrid
bla
submission
review
major
milestone
mediwound
gratifying
know
nexobrid
one
step
closer
available
help
burn
victims
united
states
said
sharon
malka
ceo
mediwound
thank
partners
commitment
important
program
look
forward
together
barda
vericel
working
fda
regulatory
review
process
seek
marketing
approval
nexobrid
united
nick
colangelo
president
ceo
vericel
added
fda
acceptance
nexobrid
bla
review
represents
another
important
milestone
toward
goal
providing
new
standard
care
eschar
removal
patients
severe
burns
brings
us
one
step
closer
providing
nexobrid
treatment
option
thousands
patients
year
suffer
burns
require
bla
submission
includes
comprehensive
set
manufacturing
data
multiple
preclinical
clinical
studies
including
pivotal
phase
detect
study
nexobrid
adult
patients
deep
partial
thermal
burns
total
body
surface
area
detect
study
successfully
met
primary
endpoint
secondary
endpoints
comparable
safety
profile
nexobrid
approved
european
union
international
markets
designated
orphan
biologic
drug
united
states
european
union
international
markets
nexobrid
currently
investigational
product
united
states
vericel
corporation
nasdaq
vcel
holds
exclusive
license
north
american
commercial
rights
nexobrid
funding
technical
support
development
nexobrid
provided
biomedical
advanced
research
development
authority
barda
vericel
commercial
partner
host
virtual
analyst
investor
day
friday
october
est
focus
nexobrid
include
discussions
burn
surgeon
thought
leaders
current
burn
debridement
practices
nexobrid
upon
approval
could
change
current
treatment
paradigm
debridement
severe
thermal
burns
nexobrid
nexobrid
concentrate
proteolytic
enzymes
enriched
bromelain
topically
administered
biological
product
enzymatically
removes
nonviable
burn
tissue
eschar
patients
deep
partial
thermal
burns
within
four
hours
application
without
harming
viable
tissue
nexobrid
approved
european
union
international
markets
designated
orphan
biologic
drug
united
states
european
union
international
markets
vericel
holds
exclusive
license
north
american
commercial
rights
nexobrid
january
mediwound
announced
positive
results
acute
phase
pivotal
phase
clinical
study
detect
nexobrid
adult
patients
deep
thermal
burns
percent
total
body
surface
area
study
met
primary
endpoint
complete
eschar
removal
compared
gel
vehicle
well
secondary
endpoints
compared
standard
care
soc
including
shorter
time
eschar
removal
lower
incidence
surgical
eschar
removal
lower
blood
loss
eschar
removal
safety
endpoints
including
key
safety
endpoint
time
complete
wound
closure
compared
patients
treated
soc
also
achieved
addition
safety
data
cosmesis
function
found
comparable
treatment
soc
arms
new
safety
signals
observed
june
bla
submitted
fda
seeking
approval
eschar
removal
debridement
adults
deep
thermal
burns
additional
long
term
safety
follow
data
submitted
safety
labeling
update
part
commitment
mediwound
mediwound
biopharmaceutical
company
focused
developing
manufacturing
commercializing
novel
therapeutics
based
patented
proteolytic
enzyme
technology
address
unmet
needs
fields
severe
burns
chronic
wounds
mediwound
first
innovative
biopharmaceutical
product
rapidly
removes
burn
eschar
without
harming
viable
tissue
product
received
marketing
authorization
european
medicines
agency
well
israeli
argentinian
south
korean
russian
peruvian
ministries
health
mediwound
second
innovative
product
topical
biological
drug
candidate
debridement
chronic
wounds
using
proteolytic
enzyme
technology
nexobrid
two
phase
studies
escharex
demonstrated
safety
efficacy
debridement
various
chronic
wounds
within
daily
applications
information
please
visit
barda
biomedical
advanced
research
development
authority
barda
part
office
assistant
secretary
preparedness
response
within
department
health
human
services
provides
integrated
systematic
approach
development
purchase
necessary
vaccines
drugs
therapies
diagnostic
tools
public
health
medical
emergencies
information
refer
barda
funding
technical
support
development
nexobrid
including
expanded
access
treatment
protocol
next
pivotal
phase
clinical
study
detect
marketing
approval
registration
process
nexobrid
provided
biomedical
advanced
research
development
authority
barda
assistant
secretary
preparedness
response
aspr
within
department
health
human
services
hhs
ongoing
usg
contract
additional
projects
evaluation
nexobrid
funded
barda
contract
include
randomized
controlled
pivotal
clinical
trial
use
pediatric
population
establishment
use
data
package
development
health
economic
model
evaluate
cost
savings
impact
enable
market
adoption
united
states
cautionary
note
regarding
statements
mediwound
caution
statements
statements
historical
fact
included
press
release
address
activities
events
developments
expect
believe
anticipate
may
occur
future
statements
although
believe
reasonable
basis
statements
contained
herein
based
current
expectations
future
events
affecting
us
subject
risks
assumptions
uncertainties
factors
difficult
predict
many
beyond
control
actual
results
may
differ
materially
expressed
implied
statements
press
release
statements
often
always
made
use
words
phrases
anticipates
intends
estimates
plans
expects
continues
believe
guidance
outlook
target
future
potential
goals
similar
words
phrases
future
conditional
verbs
would
could
may
similar
expressions
specifically
press
release
contains
statements
concerning
anticipated
progress
development
objectives
expectations
commercial
potential
nexobrid
escharex
among
factors
may
cause
results
materially
different
stated
herein
inherent
uncertainties
associated
timing
conduct
clinical
trial
product
development
activities
timing
likelihood
regulatory
approvals
ability
successfully
develop
commercialize
nexobrid
including
commercial
growth
potential
market
demand
product
availability
funding
barda
agreement
mediwound
use
connection
nexobrid
development
activities
timing
nexobrid
delivery
barda
expected
payments
license
agreement
vericel
competitive
developments
whether
fda
accept
part
bla
provide
marketing
approval
nexobrid
united
states
risks
related
timing
conduct
next
study
ability
successfully
develop
commercialize
escharex
design
phase
study
timing
interim
assessment
impact
applicable
laws
regulations
uncertainties
associated
scope
scale
duration
impact
pandemic
example
unable
predict
pandemic
affect
overall
healthcare
infrastructure
including
pace
governmental
agencies
fda
review
approve
regulatory
submissions
additional
quarantines
requirements
shelter
home
incremental
mitigation
efforts
also
may
impact
ability
source
supplies
operations
ability
capacity
manufacture
sell
support
use
nexobrid
future
significant
factors
discussed
greater
detail
mediwound
annual
report
form
year
ended
december
filed
securities
exchange
commission
sec
february
quarterly
reports
form
filings
sec
statements
reflect
mediwound
current
views
date
hereof
mediwound
undertakes
specifically
disclaims
obligation
update
statements
reflect
change
respective
views
events
circumstances
occur
date
release
except
required
law
